Synergistic inhibition of HIV-1 reverse transcriptase and HIV-1 replication by combining trovirdine with AZT, ddl and ddC in vitro

Antiviral Chemistry and Chemotherapy

Volumn 7, Issue 5, 1996, Pages 221-229

  Zhang, H ^a,b   Vrang, L ^a   Rydergard C ^a   Ahgren C ^a   Oberg B ^a,b  

^a MEDIVIR AB   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Combination; HIV; Inhibitor; Mutants; Reverse transcriptase; Trovirdine

Indexed keywords

2',3' DIDEOXYADENOSINE TRIPHOSPHATE; 2',3' DIDEOXYCYTIDINE 5' TRIPHOSPHATE; 2',3' DIDEOXYGUANOSINE TRIPHOSPHATE; 2',3' DIDEOXYINOSINE TRIPHOSPHATE; 2',3' DIDEOXYTHYMIDINE TRIPHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; FOSCARNET; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TROVIRDINE; UNCLASSIFIED DRUG; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE; ZIDOVUDINE 5' TRIPHOSPHATE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL FREE SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0029756588     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029600700501     Document Type: Article

References (42)

1. Åhgren, C., Bäckbro, K., Bell, F.W., Cantrell, A.S., Clemens, M., Colacino, J., Deeter, J.B., Engelhardt, J.A., Högberg, M., Jaskunas, S.R., Johansson, N.-G., Jordan, C.L., Kasher, J.S., Kinnick, M.D., Lind, P., Lopez, C., Morin Jr, J.M., Muesing, M.A., Noreen, R., Öberg, B., Paget, C.J., Parrish, C., Pranc, P., Rippy, M., Rydergård, C., Sahlberg, C., Swanson, S., Tang, J., Ternansky, R.J., Unge, T., Vasileff, R.T., West, S.J., Vrang, L., Zhang, H., and Zhou, X.-X. (1995) A new class of potent nonnucleoside inhibitor of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 39(6): 1329-1335.
2. Antonelli, G., Dianzani, F., Bellarosa, D., Turriziani, O., Riva, E., and Gentile, A. (1994) Drug combination of AZT and ddl: synergism of action and prevention of appearance of AZT-resistance. Antiviral Chem Chemother 5: 51-55.
3. Bacolla, A., Shin, C.-K., Rose, J.M., Piras, G., Warren, T.C., Grygon, C.A., Ingraham, R.H., Cousins, R.C., Greenwood, D.J., Richman, D., Cheng, Y.-C., and Griffin, J.A. (1993) Amino acid substitution in HIV-1 reverse transcriptase with corresponding residue from HIV-2. Biol Chem 258: 16571-16577.
4. Buckheit Jr, R.W., White, E.L., Germany-Decker, J., Allen, L.B., Ross, L.J., Shannon, W.M., Janssen, P.A.J., and Chirigos, M.A. (1994) Cell-based and biochemical analysis of combination of 3′-azido-3′-deoxythymidine and analogues of TIBO. Antiviral Chem Chemother 5: 35-42.
5. Byrnes, V.W., Emini, E.A., Schleif, W.A., Condra, J.H., Schneider, C.L., Long, W.J., Wolfgang, J.A., Graham, D.J., Gottlib, L., Schlabach, A.J., Wolanski, B.S., Blahy, O.M., Quintero, J.C., Rhodes, A., Roth, E., Titus, D.L., and Sardana, V.V. (1994) Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors. Antimicrob Agents Chemother 38: 1404-1407.
6. Chong, K.-T., Pagano, P.J., and Hinshaw, R.R. (1994) Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibit human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother 38: 288-293.
7. Chou, T.-C., and Talalay, P. (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115: 207-216.
8. Chou, T.-C., and Talalay, P. (1983) Analysis of combined drug effects: a new look at a very old problem. TIPS: 450-454.
9. Chou, T.-C., and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitor. Adv Enzyme Regul 22: 27-55.
10. Debyser, Z., De Vreese, K., Knops-Gerrits, P.P., Baekelandt, V., Bhikhabhar, R., Strandberg, B., Pauwels, R., Annè, J., Desmyter, J., and De Clercq, E. (1993) Kinetic of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus 1-specific reverse transcriptase inhibitors. Mol Pharmacol 43: 521-526.
11. De Clercq, E. (1991) Basic approaches to anti-retroviral treatment. J AIDS 4: 207-218.
12. De Clercq, E. (1992) HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 8: 119-131.
13. De Clercq, E. (1995a) Antiviral therapy for human immunodeficiency virus infections. Clin Microb Reviews 8: 200-239.
14. De Clercq, E. (1995b) Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J Med Chem 38: 2491-2517.
15. Dueweke, T.J., Pushkarskaya, T., Poppe, S.M., Zhao, J.-Q., Cheng, I.S.Y., Stevenson, M., and Tarpley, W.G. (1993) A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confer increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 90: 4713-4717.
16. Frank, K.B., Derse, D.D., Bastow, K.F., and Cheng, Y.-C. (1984) Novel interaction of aphidicolin with herpes simplex virus DNA polymerase and polymerase-associated exonuclease. J Biol Chem 269: 13282-13286.
17. Goldman, M.E., Nunberg, J.H., O'Brien, J.A., Quintero, J.C., Schleif, W.A., Freund, K.F., Gaul, S.L., Saari, W.S., Wai, J.S., Hoffman, J.M., Anderson, P.S., Hype, D.J., Emini, E.A., and Stern, A.M. (1991) Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Nail Acad Sci USA 88: 6863-6867.
18. Goldman, M.E., O'Brien, J.A., Ruffing, T.L., Nunberg, J.H., Schleif, W.A., Quintero, J.C., Siegl, P.K.S., Hoffman, J.M., Smith, A.M., and Emini, E.A. (1992) L-697,229 specifically inhibits Human Immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob Agents Chemother 36: 1019-1023.
19. Kohlstaedt, L.A., Wang, J., Friedrnan, J.M., Rice, P.A., Steitz, T.A. (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1783-1790.
20. Kong, X.-B., Zhu, Q.-Y., Ruprecht, R.M., Watanabe, K.A., Zeidler, J.M., M. Gold, J.M., Polsky, B., Armstrong, D., and Chou, T.-C. (1991) Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3′-azido-3′-deoxythymidine, phosphonoformate, and 2′,3′-dideoxythymidine. Antimicrob Agents Chemother 35: 2003-2011.
21. Larder, B.A., Kemp, S.D., and Hauigen, P.R. (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
22. Martin, J.L., Wilson, J.E., Haynes, R.L., and Furman, P.A. (1993) Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc Natl Acad Sci USA 90: 6135-6139.
23. Mathez, D., Schinazi, R.D., Liotta, D.C., and Leibowitch, J. (1993) Infectious amplification of wild type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother 37: 2206-2211.
24. Nunberg, J.K., Schleif, W.A., Boots, E.J., O'Brien, J.A., Quintero, J.C., Hoffman, J.M., Emini, E.A., and Goldman, M.E. (1991) Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 65: 4887-4892.
25. Richman, D., Rosenthal, A.S., Skoog, M., Eckner, R.J., Chou T.-C., Sabo, J.P., and Merluzzi, V.J. (1991) BI-RG-537 is active against zidovudine resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 35: 305-308.
26. Romero, D.L., Busso, M., Tan, C.-K., Reusser, F., Palmer, J.R., Poppe, S.M., Aristoff, P.A., Downey, K.M., So, A.G., Resnick, L., and Tarpley, W.G. (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 88: 8806-8810.
27. Sandström, E., and Öberg, B. (1993a) Antiviral therapy in human immunodeficiency virus infections, Current status (Part I). Drugs 45(4): 488-508.
28. Sandström, E., and Öberg, B. (1993b) Antiviral therapy in human immunodeficiency virus infections, Current status (Part II). Drugs 45(5): 637-653.
29. Schinaizi, R.F. (1993) Drugs and multitherapies of the future for HIV-1: can cell-based assays predict their efficacy in humans. International Antiviral News 1: 1-3.
30. Schinaizi, R., Larder, B., and Mellor, J. (1994) Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. International Antiviral News 2: 72-75.
31. Spence, R.A., Kati, W.M., Anderson, K.S., and Johnson, K.A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267: 988-993.
32. Starnes, M.C., and Cheng, Y.-C. (1988) Inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxynucleoside triphosphate: Template dependence and combination with phosphonofarmate. Virus Genes 2(3): 242-251.
33. Studier, F.W., Rosenberg, A.H., Dunn, J.J., and Dubendorff, J.W. (1990) Use of T7 DNA polymerase to direct expression of cloned genes. Methods Enzymol 185: 60-89.
34. Tramontano, E., and Cheng, Y.-C. (1992) HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem Pharmacol 43: 1370-1376.
35. Unge, T., Ahola, H., Bhikhabhai, R., Bäckbro, K., Lövgren, S., Fenyö, E.M., Honigman, A., Panet, A., Gronowitz, G.S., and Strandberg, B. (1990) Expression, purification and crystallisation of the HIV-1 reverse transcriptase (RT). AIDS Res Hum Retrovirus 6: 1297-1303.
36. Unge, T., Knight, S., Bhikhabhai, R., Lövgren, S., Dauter, Z., Wilson, K., and Strandberg, B. (1994) 2.2 Å resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (finger and palm subdomains). Structure 2: 953-961.
37. Weislow, O.S., Kiser, R., Fine, D.L., Bader, J., Shoemaker, R.H., and Boyd, M.R. (1989) New soluble-formazan assay for HIV-1 cytopathic effect: application to high-flux screening and natural products AIDS-antiviral activity. J Natl Cancer Inst 81: 577-586.
38. White, E.L., Buckheit, Jr., R.W., Ross, L.J., Germany, J.M., Andries, K., Pauwel, R., Janssen, P.A.J., Shannon, W.M., and Churigos, M.A. (1991) A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer template. Antiviral Res. 16: 257-266.
39. Young, S.D. (1993) Non-nucleoside inhibitors of HIV-1 reverse transcriptase. Perspectives in drug discovery and design. 1: 181-192.
40. Zhang, H., Vrang, L., Unge, T., and Öberg, B. (1993) Characterization of HIV reverse transcriptase with Tyr181→Cys and Leu100→IIe mutations. Antiviral Chem Chemother 4: 301-308.
41. Zhang, H., Vrang, L., Bäckbro, K., Unge, T., Noréen, R., and Öberg, B. (1994) Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu138→Arg and Tyr188→His mutations. Antiviral Res 24: 43-57.
42. Zhang, H., Vrang, L., Bäckbro, K., Lind, P., Sahlberg, C., Unge, T., and Öberg, B. (1995) Inhibition of wild type and mutant reverse transcriptase by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Res 28: 331-342.